Method of treating inflammation
Inventors
Chan, Phillip P. • Young, Wei-Tai • Capponi, Vincent J. • Golobish, Thomas D. • Ali, Humayra Begum
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10967001-B2
Publication Date
2021-04-06
Expiration Date
Abstract
The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer.
Core Innovation
The invention provides a method of treating systemic, regional, or local inflammation in a patient by administering a therapeutically effective dose of a sorbent for an inflammatory mediator in the patient. The sorbent is a biocompatible polymer designed to sequester inflammatory mediators, including cytokines produced in response to infection. The method is implemented by administering the sorbent orally, via a feeding tube, peritoneally, or rectally.
The biocompatible polymer comprises residues from one or more monomers selected from divinylbenzene, ethylvinylbezene, styrene, ethylstyrene, and mixtures thereof. The polymer has a pore structure such that the total pore volume of pore size in the range of 50 Å to 3000 Å is greater than 0.5 cc/g to 3.0 cc/g dry polymer. The polymer further satisfies specified pore-volume ratio constraints comparing pore-volume across selected pore diameter ranges.
The inflammatory mediator is a cytokine produced in response to infection in the patient, chosen from endotoxemia and multiple pathogen- or toxin-associated causes. The list includes Bacillus anthracis (anthrax), influenza virus, smallpox virus, Yersinia pestis (plague), Ebola virus, Marburg virus, Francisella tularensis (tularemia), hantavirus, cholera toxin, botulinum toxin, ricin toxin, Salmonella, Escherichia coli, Shigella, and Listeria.
Claims Coverage
The independent claim covers a method for treating systemic, regional, or local inflammation using a biocompatible polymer sorbent targeted to infection-associated cytokines. It combines five inventive features: the treatment method, the polymer composition, the pore-structure constraints, the administration routes, and the specified cytokine sources.
Sorbent-mediated treatment of systemic, regional, or local inflammation
A method of treating systemic, regional, or local inflammation in a patient comprising administration of a therapeutically effective dose of a sorbent for an inflammatory mediator in the patient, where the sorbent is a biocompatible polymer.
Monomer-residue biocompatible polymer composition
The biocompatible polymer comprises residues from one or more monomers selected from divinylbenzene, ethylvinylbezene, styrene, ethylstyrene, and mixtures thereof.
Pore structure with total pore-volume and pore-volume ratio constraints
The biocompatible polymer has a pore structure such that the total pore volume of pore size in the range of 50 Å to 3000 Å is greater than 0.5 cc/g to 3.0 cc/g dry polymer, with specified pore-volume ratio constraints across selected pore diameter ranges.
Administration routes for delivering the sorbent
The sorbent is administered orally, via a feeding tube, peritoneally, or rectally.
Cytokine as infection-associated inflammatory mediator selected from specified causes
The inflammatory mediator is a cytokine produced in response to an infection in the patient chosen from endotoxemia and the listed pathogens and toxins including Bacillus anthracis (anthrax), influenza virus, smallpox virus, Yersinia pestis (plague), Ebola virus, Marburg virus, Francisella tularensis (tularemia), hantavirus, cholera toxin, botulinum toxin, ricin toxin, Salmonella, Escherichia coli, Shigella, and Listeria.
Across the independent claim, the inventive approach centers on administering a therapeutically effective dose of a biocompatible polymer sorbent for inflammatory cytokines. The claim further requires a specified monomer-residue composition, quantitative pore-volume and pore-volume ratio constraints, administration via oral, feeding tube, peritoneal, or rectal routes, and cytokines selected from a defined list of infection-associated causes.
Stated Advantages
Treats systemic, regional, or local inflammation by administering a therapeutically effective sorbent for inflammatory mediators such as cytokines.
Documented Applications
Treating sepsis and septic shock via administration of an oral porous polymer in a CLP sepsis model.
Treating inflammatory bowel disease using a TNBS colitis model regimen.
Binding or targeting Botulinum neurotoxin A1 (BoNT/A1) using an in vitro binding example.
Interested in licensing this patent?